LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies.RMD Open已检查 6 张 PubMed Figure,均未识别为 KM 图:Figure 1:ROC 图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:AI 判定为 other;Figure 5:ROC 图;另有 1 张未列出。 | PMID 41506743PMC13059902 | 2026-Jan-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.Nat Commun已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。 | PMID 41501026PMC12881390 | 2026-Jan-07 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of Cinainu in paediatric alopecia areata: an international, double-blind, randomized, placebo-controlled, phase II/III trial.Br J Dermatol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40668972无 PMCID | 2026-Jan-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement.Br J DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40875818无 PMCID | 2026-Jan-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency: results from an open-label extension of a phase 3 study.Endocr J疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图;另有 1 张未列出。 | PMID 41183961PMC12819071 | 2026-Jan-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial.JAMA疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41324946PMC12670262 | 2026-Jan-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Differential Effect of Ticagrelor Versus Clopidogrel by Causative Classification of Stroke Classification and Vascular Cellular Adhesion Molecule-1 Level on the Risk of Recurrent Stroke: A Post Hoc Analysis of the CHANCE-2 Trial.J Am Heart Assoc | PMID 41413755PMC12909013 | 2026-Jan-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Safety, immunogenicity, and relative efficacy of a parenteral trivalent rotavirus subunit vaccine candidate (TV P2-VP8) in healthy Ghanaian, Malawian, and Zambian infants.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41319434无 PMCID | 2026-Jan-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Exploring Trial Endpoints in Geographic Atrophy Based on Localized Functional Changes in Microperimetry and AI-Quantified OCT Biomarkers.Invest Ophthalmol Vis Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图。 | PMID 41533918PMC12805968 | 2026-Jan-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.LancetPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41314226无 PMCID | 2026-Jan-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Survival Outcomes of NCRT With Surgery vs Surgery With Adjuvant Therapy for ESCC: A Single-Center Prospective Phase 3 Randomized Clinical Trial.JAMA Netw Open | PMID 41490111PMC12771256 | 2026-Jan-02 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis.Hepatology入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40053863PMC12443161 | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP05 Trial.Ann Surg | PMID 40235447PMC12695294 | 2026-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine.Pain Med已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。 | PMID 40627411PMC12773742 | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Randomized, double-blind phase III trial of a dexamethasone-free regimen for managing highly emetogenic chemotherapy-induced nausea and vomiting.Int J CancerPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40735921无 PMCID | 2026-Jan-01 | 0.95 | While the record meets criteria for oncology, human, randomized, phase III, drug intervention, and original result, it fails the core eligibility requirement of having a primary/key secondary time-to-event efficacy endpoint. The primary endpoint is a binary response rate (complete response rate), and no time-to-event analysis (e.g., Kaplan-Meier, HR) is mentioned for any endpoint. | 无 KM 图 |
| Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40752655无 PMCID | 2026-Jan-01 | 0.90 | The record describes a Phase III randomized trial in breast DCIS with a time-to-event primary endpoint. However, the intervention is radiation therapy (a non-drug technique), and the reported results are for secondary endpoints (toxicity and quality of life). The eligibility criteria require a drug-containing intervention and an original report of the primary or key secondary efficacy endpoint. This report does not meet the drug intervention criterion. | 无 KM 图 |
| HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results.Int J Radiat Oncol Biol PhysPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40780546无 PMCID | 2026-Jan-01 | 0.95 | The record is from a definitive Phase III randomized oncology trial in humans, but it reports only acute toxicity results and does not include the survival or time-to-event efficacy outcomes required for the Kaplan-Meier digitization cohort. | 无 KM 图 |
| Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.Haematologica | PMID 40820816PMC12775767 | 2026-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:非 KM 图;Figure 2.:非 KM 图。 | PMID 40829719PMC12637033 | 2026-Jan-01 | 0.85 | The report is from a Phase III randomized oncology trial with drug intervention, but the reported results are for a patient-reported secondary endpoint (hearing handicap), not a time-to-event efficacy endpoint. The deterministic review correctly identified no time-to-event signal. | 无 KM 图 |
| Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.J RheumatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40953957无 PMCID | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis.Inflamm Bowel Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1.:非 KM 图;Figure 2.:非 KM 图。 | PMID 40997114PMC12759055 | 2026-Jan-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid.Inflamm Bowel Dis疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Figure 1.:AI 判定为 flow diagram;Figure 2.:非 KM 图;Figure 3.:非 KM 图;Figure 4.:非 KM 图;Figure 5.:非 KM 图;另有 1 张未列出。 | PMID 41003640PMC12759051 | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Early palliative care for patients with glioblastoma: A randomized phase III clinical trial (EPCOG).Neuro Oncol | PMID 41071052PMC12962646 | 2026-Jan-01 | 0.95 | The study is a Phase III randomized trial in glioblastoma (oncology, human), but it fails two key eligibility criteria: 1) The primary endpoint is quality-of-life (FACT-Br), not a time-to-event efficacy endpoint. 2) The intervention is early palliative care (non-drug), not a drug-containing regimen. Therefore, it is not eligible for the oncology KM digitization cohort. | 已完成 |
| Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41104938无 PMCID | 2026-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41124220无 PMCID | 2026-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension.J Hypertens疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:非 KM 图;FIGURE 3:AI 判定为 other。 | PMID 41195725PMC12672029 | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension.JAMA Cardiol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:Figure 1.:森林图/亚组分析图;Figure 2.:森林图/亚组分析图;Figure 3.:生活质量量表图;Figure 4.:非 KM 图。 | PMID 41205147PMC12596743 | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41223690无 PMCID | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial.J HypertensPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41231022无 PMCID | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Neonatal BCG vaccination to prevent respiratory infections in the first 5 years of life: results from the MIS BAIR randomised controlled trial.Vaccine疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41337911无 PMCID | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy, safety, and immunogenicity of UB-851 versus ® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial.J Chin Med Assoc疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Fig. 1:非 KM 图;Fig. 2:非 KM 图。 | PMID 41396155PMC12815523 | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials.Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 41420831无 PMCID | 2026-Jan-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Topical Efinaconazole 10% for Onychomycosis: Pooled Phase 3 Analysis in White, Black, and Asian Participants.J Drugs DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41493257无 PMCID | 2026-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).Endocr Relat Cancer | PMID 41524552PMC12872296 | 2026-Jan-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.Nat Med入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 41495411PMC12823417 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Finerenone Across the Spectrum of Kidney Risk in Heart Failure: The FINEARTS-HF Trial.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40208137无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study.JACC Heart FailPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40338768无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Systemic Inflammatory Markers Correlate with Chronic Kidney Disease-Associated Pruritus and Response to Treatment.J Invest Dermatol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40409676无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A clinical study of ten-year prognosis in patients with lumbar disc herniation treated with condoliase in a phase III trial.J Orthop SciPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40664535无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ovarian stimulation with follitropin delta is safe and effective: results from the RITA randomized, double-blind, placebo-controlled trials.Fertil SterilPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40714031无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of IncobotulinumtoxinA for Treatment of Sialorrhea: A Multicenter, Phase 3 Study in Japan.Mov Disord Clin Pract入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40771035PMC12839494 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.Aliment Pharmacol Ther已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 multi panel km;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。 | PMID 40793974PMC12690228 | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A Randomized Sham-Controlled Phase 2/3 Trial of QPI-1007 for Acute Nonarteritic Anterior Ischemic Optic Neuropathy.OphthalmologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40816607无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Comparison of patient-reported outcomes in patients achieving complete versus near-complete skin clearance following Vunakizumab treatment: a post-hoc analysis of a phase III trial.Naunyn Schmiedebergs Arch Pharmacol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40853464无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial.OphthalmologyPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40876598无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Perfluorohexyloctane Eye Drops in Premenopausal and Postmenopausal Women with Dry Eye Disease Associated with Meibomian Gland Dysfunction: A Post Hoc Analysis of a Phase 3 Trial.Curr Eye ResPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40898391无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Pooled data from phase 3 clinical trials comparing the clinical activity of ceftolozane/tazobactam versus meropenem for the treatment of complicated intra-abdominal infections.Infect Dis (Lond)PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40913503无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial.Lancet Infect DisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40945526无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Efficacy and safety of a China-developed live attenuated herpes zoster vaccine in Chinese healthy adults aged 40 years and older: a multicentre, randomized, double-blind, placebo-controlled, phase 3 clinical trial.Clin Microbiol InfectPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40962113无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial.J Am Acad DermatolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40976531无 PMCID | 2026-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |